The licence will enable research that will give a deeper understanding of psychedelic mushrooms and their interaction with the human body.
Numinus Wellness is expanding its psychedelic research with the receipt of a biosecurity licence. The Public Health Agency of Canada has approved the Containment Level 2 (CL2) pathogens and toxins licence. The licence approval follows an upgrade of the company’s facility.
Numinus Wellness, which is hosting an extension of the MAPS-sponsored trial exploring MDMA-assisted therapy for post-traumatic stress disorder (PTSD), will now be able to contribute novel data on natural psychedelics, present additional IP opportunities and add another revenue driver through contract research services.
Science officer and general manager at Numinus Bioscience, Sharan Sidhu, commented: “This biosecurity expansion will allow us to deeply understand not only the mechanisms behind psilocybe mushrooms and other naturally occurring psychedelic materials but also their interaction with the human body.
“By performing testing and validation at a highly precise level, we will advance both our own IP development of finished products and scaled production processes, as well as contract services and sale of materials to research and industry partners.”
CEO and founder of Numinus Wellness, Payton Nyquvest, commented: “With this new license, Numinus is more committed than ever to advancing psychedelic research from theory to practice.
“By investigating optimal growth, bioavailability and pharmacokinetics, we are moving closer to developing therapeutics at scale to support accessible psychedelic-assisted therapy.”
The licence is in addition to Numinus Bioscience’s existing Controlled Drugs and Substances Dealer’s License from Health Canada. It will also help the company’s plans of establishing a centre of excellence for natural psychedelic research, including extensive license amendments and investment into state-of-the-art equipment such as the Orbitrap, which identifies metabolites in the body and will play a key role in the PK and pre-clinical studies.
[activecampaign form=52]
